Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...

MetaVia has shared an update on its attempt to crash the obesity party, reporting average weight loss of 9.1% in people who ...

Ascletis Pharma has received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to begin ...

Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical stage global biopharmaceutical company that develops and delivers ...

"MetaVia OXM analogue agonist meets endpoints in Phase Ib weight loss trial" was originally created and published by Clinical ...

BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...

Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced that the first patient has been ...

Panelists discuss how clinicians are beginning to integrate xanomeline/trospium into practice for patients who have struggled ...

Designing STEM classrooms that encourage students to reflect on their progress and share their stories takes intention, but ...

Safety in pediatric sedation relies on strict guidelines and monitoring, so let's learn how providers utilize pharmacological ...

The first sublingual therapy for the intermittent treatment of uncontrolled OFF episodes for adult people living with Parkinson’s Disease ...